Expanding Pfizer’s Oncology Portfolio: Insights from Our Latest Pfizer Pflash Webcast

August 21, 2025

At Pfizer, we are committed to driving meaningful advancements in cancer care – with a significant percentage of our R&D budget dedicated to Oncology.

In support of this goal, Pfizer recently closed an exclusive licensing agreement with 3SBio, providing us with global, ex-China rights to develop, manufacture and commercialize a novel bispecific antibody, SSGJ-707. This agreement further strengthens our Oncology pipeline and advances our ability to deliver potentially transformative treatments for some of the world’s most common cancers.

So what makes SSGJ-707 unique? This new therapeutic agent combines two established cancer-fighting approaches into one investigational medicine with the potential to achieve superior efficacy in certain types of solid tumors. SSGJ-707 has already shown promising initial efficacy and safety data in Phase 2 clinical trials, and we believe it could be transformational for many people living with cancer, if successful in clinical trials and approved.

In the latest Pfizer Pflash, Francesca DeMartino, Pfizer's Chief Investor Relations Officer, sat down with Jeff Legos, Pfizer’s Chief Oncology Officer, to discuss SSGJ-707, why it is a seamless addition to Pfizer’s Oncology portfolio, and the next steps for developing this promising molecule.

Watch this video with Dr. Legos for the key takeaways from our Pfizer Pflash on this potentially transformative investigational therapy.

For more information on our licensing agreement with 3SBio and the significant potential we see with SSGJ-707, we invite you to watch the full Pfizer Pflash.

Forward-looking statements included herein and in the linked content, including those related to our anticipated operating and financial performance, including our financial guidance, our product and pipeline advancements, our strategic priorities, our cost realignment program and our efforts to return value to shareholders, speak only as of the original date they were made and are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.

Forward-looking statements included herein are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.

Copyright © 2002 – 2025 Pfizer Investor Insights All rights reserved. This information—including product information—is intended only for residents of the United States. The products discussed herein may have different labeling in different countries. This website contains certain information about Pfizer, but may not contain all information that is material to Pfizer.